TrialJournal for immunotherapy of cancer2022

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.

Brian I Rini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.